Adamas is a pharmaceutical company that is developing new medicines to improve the daily lives of those affected by chronic neurologic disorders, including Alzheimer's disease, Parkinson's disease (PD), multiple sclerosis and epilepsy. Adamas has pioneered a platform based on an understanding of time dependent biologic effects of disease activity and drug response to provide demonstrable symptomatic relief without additional tolerability issues. By utilizing this approach, we have developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders.
Our lead program, ADS-5102 in development for levodopa-induced dyskinesia (LID) in patients with PD, is currently being evaluated by the U.S. Food and Drug Administration (FDA) for potential approval in 2017. ADS-5102 has additional potential opportunities in chronic neurologic indications such as multiple sclerosis walking impairment, post stroke walking impairment, and several other indications. Also, ADS-4101 is being investigated for the improved control of epileptic seizures. Additionally, through our license agreement to Allergan, the company is eligible to receive royalties on sales of NAMENDA XR® and NAMZARIC® beginning in June of 2018 and May of 2020, respectively.
NAMENDA XR® and NAMZARIC® are trademarks of Merz Pharma GmbH & Co. KGaA.